+关注
thekang
暂无个人介绍
IP属地:未知
201
关注
26
粉丝
0
主题
0
勋章
主贴
热门
thekang
2021-11-13
Like and comment
Buy the Elon Musk Dip in Tesla Stock?
thekang
2021-11-11
$Oatly Group AB(OTLY)$
hhow is this not gaining traction?
thekang
2021-10-30
$GLOBALFOUNDRIES Inc.(GFS)$
could this go all the way?
thekang
2021-10-27
$Progenity, Inc.(PROG)$
short or all in
thekang
2021-10-26
$Roku Inc(ROKU)$
Where's the potential
thekang
2021-10-26
$GLOBALFOUNDRIES Inc.(GFS)$
Get ready to put in
thekang
2021-10-25
$Digital World Acquisition Corp(DWAC)$
crazy movements
thekang
2021-10-25
$Tiger Brokers(TIGR)$
ddont panicd just hodl
thekang
2021-10-22
$Devon(DVN)$
hhOly oil cow making waves
thekang
2021-10-05
$Clover Health Corp(CLOV)$
bounce bounce
thekang
2021-09-29
$Microvast Holdings, Inc.(MVST)$
bbuy on the dip
thekang
2021-09-28
$Pinterest, Inc.(PINS)$
sso much for buying on the dip when it dipped further
thekang
2021-09-27
Like comment
抱歉,原内容已删除
thekang
2021-09-27
$Activision Blizzard(ATVI)$
RReallt bruh
thekang
2021-09-25
Good way
IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.
thekang
2021-09-25
$Oracle(ORCL)$
good recovery and stable
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3579391473717940,"uuid":"3579391473717940","gmtCreate":1616298584345,"gmtModify":1618714250465,"name":"thekang","pinyin":"thekang","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":26,"headSize":201,"tweetSize":201,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":879488314,"gmtCreate":1636763712834,"gmtModify":1636763712977,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/879488314","repostId":"1169510701","repostType":4,"repost":{"id":"1169510701","pubTimestamp":1636759821,"share":"https://www.laohu8.com/m/news/1169510701?lang=&edition=full","pubTime":"2021-11-13 07:30","market":"us","language":"en","title":"Buy the Elon Musk Dip in Tesla Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=1169510701","media":"TheStreet","summary":"Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk","content":"<p>Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk continues to sell.</p>\n<p>Tesla shares have been incredibly volatile this week. The stock fell 2.8% on Friday as investors try to sort out the next direction.</p>\n<p>Amid the recent slide — and perhaps one could say it triggered the decline — is CEO Elon Musk’s recent selling.</p>\n<p>Over the weekend, Musk ran a Twitter pollasking if he should sellsome of his shares.</p>\n<p>That led to a near-5% decline in Monday’s session, followed by a 12% haircut on Tuesday.</p>\n<p>He had sold more than $5 billion worth of stock earlier this week. Another $650 million was reported this morning.</p>\n<p>Referencing when I said “perhaps” Musk caused the recent selloff, many will say that is indeed the case and there’s no need to leave it to question.</p>\n<p>That may be true in some regards, but the stock shifted into a parabolic state this quarter.</p>\n<p>From Oct. 25 to the Nov. 4 high — covering just nine trading sessions — shares gained more than 30%.</p>\n<p>From Oct. 1 to those highs, the gain swells to almost 63%, while the run from the Aug. 17 low made less than three months sit at more than 91%.</p>\n<p>In other words, yes, the Musk headlines may have triggered the selling. But after such a meteoric run and after garnering a $1.2 trillion valuation near the high, Tesla stock was due for a correction regardless of which headline caused it.</p>\n<p><b>Trading Tesla Stock</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d6b8cde52218f9b3a6d0598de04b7a6b\" tg-width=\"1023\" tg-height=\"735\" width=\"100%\" height=\"auto\"><span>Daily chart of Tesla stock.</span></p>\n<p>Look at how wobbly this name has been, as the volatility and headline risks have ramped up over that past few days.</p>\n<p>We’ll likely see some “chest-pounding” by the Tesla bears, but don’t let them fool you — this stock has been explosive on the upside. The stock is up 150% over the past year and up over 1,300% over the past three years.</p>\n<p>As one of the few U.S. companies to hit a $1 trillion market cap, it’s perhaps the furthest thing from “TeslaQ” one could imagine.</p>\n<p>Despite the run, bulls are trying to buy the dip. Shares bounced hard at the 21-day moving average, but are threatening to lose that measure today.</p>\n<p>If it does, this week’s low near $987 is vulnerable. If Tesla breaks below it, the 10-week moving average could be in play. That’s followed by the $910 gap-fill and the 50-day moving average.</p>\n<p>On the upside, let’s see if Tesla can reclaim the 10-day moving average. A close over $1,100 repairs a lot of damage and opens up the $1,200 to $1,250 area.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy the Elon Musk Dip in Tesla Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy the Elon Musk Dip in Tesla Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 07:30 GMT+8 <a href=https://www.thestreet.com/investing/trading-tesla-tsla-stock-pullback-elon-musk-insider-selling><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk continues to sell.\nTesla shares have been incredibly volatile this week. The stock fell 2.8% on ...</p>\n\n<a href=\"https://www.thestreet.com/investing/trading-tesla-tsla-stock-pullback-elon-musk-insider-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/investing/trading-tesla-tsla-stock-pullback-elon-musk-insider-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169510701","content_text":"Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk continues to sell.\nTesla shares have been incredibly volatile this week. The stock fell 2.8% on Friday as investors try to sort out the next direction.\nAmid the recent slide — and perhaps one could say it triggered the decline — is CEO Elon Musk’s recent selling.\nOver the weekend, Musk ran a Twitter pollasking if he should sellsome of his shares.\nThat led to a near-5% decline in Monday’s session, followed by a 12% haircut on Tuesday.\nHe had sold more than $5 billion worth of stock earlier this week. Another $650 million was reported this morning.\nReferencing when I said “perhaps” Musk caused the recent selloff, many will say that is indeed the case and there’s no need to leave it to question.\nThat may be true in some regards, but the stock shifted into a parabolic state this quarter.\nFrom Oct. 25 to the Nov. 4 high — covering just nine trading sessions — shares gained more than 30%.\nFrom Oct. 1 to those highs, the gain swells to almost 63%, while the run from the Aug. 17 low made less than three months sit at more than 91%.\nIn other words, yes, the Musk headlines may have triggered the selling. But after such a meteoric run and after garnering a $1.2 trillion valuation near the high, Tesla stock was due for a correction regardless of which headline caused it.\nTrading Tesla Stock\nDaily chart of Tesla stock.\nLook at how wobbly this name has been, as the volatility and headline risks have ramped up over that past few days.\nWe’ll likely see some “chest-pounding” by the Tesla bears, but don’t let them fool you — this stock has been explosive on the upside. The stock is up 150% over the past year and up over 1,300% over the past three years.\nAs one of the few U.S. companies to hit a $1 trillion market cap, it’s perhaps the furthest thing from “TeslaQ” one could imagine.\nDespite the run, bulls are trying to buy the dip. Shares bounced hard at the 21-day moving average, but are threatening to lose that measure today.\nIf it does, this week’s low near $987 is vulnerable. If Tesla breaks below it, the 10-week moving average could be in play. That’s followed by the $910 gap-fill and the 50-day moving average.\nOn the upside, let’s see if Tesla can reclaim the 10-day moving average. A close over $1,100 repairs a lot of damage and opens up the $1,200 to $1,250 area.","news_type":1},"isVote":1,"tweetType":1,"viewCount":400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870418129,"gmtCreate":1636641859614,"gmtModify":1636641860260,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OTLY\">$Oatly Group AB(OTLY)$</a>hhow is this not gaining traction?","listText":"<a href=\"https://laohu8.com/S/OTLY\">$Oatly Group AB(OTLY)$</a>hhow is this not gaining traction?","text":"$Oatly Group AB(OTLY)$hhow is this not gaining traction?","images":[{"img":"https://static.tigerbbs.com/c410eddcdf9824e4e15ae27e1e2d7f90","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870418129","isVote":1,"tweetType":1,"viewCount":513,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":840091261,"gmtCreate":1635565856126,"gmtModify":1635565856272,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>could this go all the way?","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>could this go all the way?","text":"$GLOBALFOUNDRIES Inc.(GFS)$could this go all the way?","images":[{"img":"https://static.tigerbbs.com/28b4ce6183c4644156f6ef4046ea9fe1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840091261","isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":852461804,"gmtCreate":1635297486373,"gmtModify":1635297486847,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PROG\">$Progenity, Inc.(PROG)$</a>short or all in","listText":"<a href=\"https://laohu8.com/S/PROG\">$Progenity, Inc.(PROG)$</a>short or all in","text":"$Progenity, Inc.(PROG)$short or all in","images":[{"img":"https://static.tigerbbs.com/8d60f88529049f20b5c9375c60e61edc","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852461804","isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":852683302,"gmtCreate":1635261792725,"gmtModify":1635261793220,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ROKU\">$Roku Inc(ROKU)$</a>Where's the potential","listText":"<a href=\"https://laohu8.com/S/ROKU\">$Roku Inc(ROKU)$</a>Where's the potential","text":"$Roku Inc(ROKU)$Where's the potential","images":[{"img":"https://static.tigerbbs.com/182e6ac4d835bb7e0af2eb9db23541d6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852683302","isVote":1,"tweetType":1,"viewCount":374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":852689991,"gmtCreate":1635261755078,"gmtModify":1635261756390,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Get ready to put in","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Get ready to put in","text":"$GLOBALFOUNDRIES Inc.(GFS)$Get ready to put in","images":[{"img":"https://static.tigerbbs.com/c355c8ff71101a2a48133293fdead1e8","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/852689991","isVote":1,"tweetType":1,"viewCount":1201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":856175788,"gmtCreate":1635165585294,"gmtModify":1635165585837,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DWAC\">$Digital World Acquisition Corp(DWAC)$</a>crazy movements ","listText":"<a href=\"https://laohu8.com/S/DWAC\">$Digital World Acquisition Corp(DWAC)$</a>crazy movements ","text":"$Digital World Acquisition Corp(DWAC)$crazy movements","images":[{"img":"https://static.tigerbbs.com/b185d1b16b8be8663c54dbcecef99e0d","width":"1080","height":"3148"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856175788","isVote":1,"tweetType":1,"viewCount":440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":856175880,"gmtCreate":1635165537110,"gmtModify":1635165537636,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>ddont panicd just hodl","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>ddont panicd just hodl","text":"$Tiger Brokers(TIGR)$ddont panicd just hodl","images":[{"img":"https://static.tigerbbs.com/372650c68945d62b9e598e769325bdee","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/856175880","isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":851569799,"gmtCreate":1634914953097,"gmtModify":1634914953570,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DVN\">$Devon(DVN)$</a>hhOly oil cow making waves","listText":"<a href=\"https://laohu8.com/S/DVN\">$Devon(DVN)$</a>hhOly oil cow making waves","text":"$Devon(DVN)$hhOly oil cow making waves","images":[{"img":"https://static.tigerbbs.com/127796045d4ddf75c028b2b1aa8e421a","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851569799","isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":829909950,"gmtCreate":1633446951159,"gmtModify":1633446982166,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>bounce bounce","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>bounce bounce","text":"$Clover Health Corp(CLOV)$bounce bounce","images":[{"img":"https://static.tigerbbs.com/180070dd8cf8f947865f83d5b017d79f","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829909950","isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862499943,"gmtCreate":1632898759501,"gmtModify":1632898759995,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MVST\">$Microvast Holdings, Inc.(MVST)$</a>bbuy on the dip","listText":"<a href=\"https://laohu8.com/S/MVST\">$Microvast Holdings, Inc.(MVST)$</a>bbuy on the dip","text":"$Microvast Holdings, Inc.(MVST)$bbuy on the dip","images":[{"img":"https://static.tigerbbs.com/8d84016dd94afcebe8c68554bf1062f8","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862499943","isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862304553,"gmtCreate":1632836101835,"gmtModify":1632836102014,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>sso much for buying on the dip when it dipped further ","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>sso much for buying on the dip when it dipped further ","text":"$Pinterest, Inc.(PINS)$sso much for buying on the dip when it dipped further","images":[{"img":"https://static.tigerbbs.com/8848d21d72e018cd693111dc81c9a1fe","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862304553","isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":866822925,"gmtCreate":1632754809667,"gmtModify":1632798059258,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/866822925","repostId":"1123391790","repostType":4,"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866826665,"gmtCreate":1632754772057,"gmtModify":1632798059753,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATVI\">$Activision Blizzard(ATVI)$</a>RReallt bruh","listText":"<a href=\"https://laohu8.com/S/ATVI\">$Activision Blizzard(ATVI)$</a>RReallt bruh","text":"$Activision Blizzard(ATVI)$RReallt bruh","images":[{"img":"https://static.tigerbbs.com/c1bc6fded0834787b6834b830b1e5855","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866826665","isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861772701,"gmtCreate":1632543549303,"gmtModify":1632799214056,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good way","listText":"Good way","text":"Good way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861772701","repostId":"1104085778","repostType":4,"repost":{"id":"1104085778","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632498166,"share":"https://www.laohu8.com/m/news/1104085778?lang=&edition=full","pubTime":"2021-09-24 23:42","market":"us","language":"en","title":"IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.","url":"https://stock-news.laohu8.com/highlight/detail?id=1104085778","media":"Tiger Newspress","summary":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nS","content":"<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p>\n<p><img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Company & Technology</b></p>\n<p>San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p>\n<p>Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p>\n<p>The company’s primary offerings in its Cue Integrated Care Platform:</p>\n<ul>\n <li><p>Health monitoring system</p></li>\n <li><p>Rader</p></li>\n <li><p>Cartridge</p></li>\n <li><p>Wand</p></li>\n <li><p>Data</p></li>\n <li><p>Delivery apps</p></li>\n <li><p>Enterprise dashboard</p></li>\n <li><p>Ecosystem integrations</p></li>\n</ul>\n<p>Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p>\n<p><b>Customer/User Acquisition</b></p>\n<p>The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p>\n<p>Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Expenses vs. Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Percentage</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>1.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>3.1%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>1.3%</p></td>\n </tr>\n </tbody>\n</table>\n<p>The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Efficiency Rate</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Multiple</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>100.5</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>22.9</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Market & Competition</b></p>\n<p>According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p>\n<p>This represents a forecast CAGR of 5.05% from 2021 to 2027.</p>\n<p>The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p>\n<p>Also, below is a chart showing the market share of use of detection kits by end-user type:</p>\n<p><img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>(Source)</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li><p>Abbott Laboratories(NYSE:ABT)</p></li>\n <li><p>Becton, Dickinson(NYSE:BDX)</p></li>\n <li><p>bioMerieux(OTCPK:BMXMF)</p></li>\n <li><p>Bio-Rad Laboratories(NYSE:BIO)</p></li>\n <li><p>Danaher(NYSE:DHR)</p></li>\n <li><p>Ellume Limited</p></li>\n <li><p>Everly Health</p></li>\n <li><p>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p></li>\n <li><p>Fluidigm(NASDAQ:FLDM)</p></li>\n <li><p>GenMark Diagnostics(NASDAQ:GNMK)</p></li>\n <li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Cue’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Sharply growing top line revenue</p></li>\n <li><p>Increasing gross profit and variable gross margin</p></li>\n <li><p>A swing to operating profit and net income</p></li>\n <li><p>Variable cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Total Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Total Revenue</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 201,922,000</p></td>\n <td><p>3971.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 22,953,000</p></td>\n <td><p>246.4%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Profit (Loss)</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 116,745,000</p></td>\n <td><p>2253.7%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 8,002,000</p></td>\n <td><p>20.8%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Margin</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>57.82%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>34.86%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>100.00%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Operating Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Operating Profit (Loss)</p></td>\n <td><p>Operating Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 79,463,000</p></td>\n <td><p>39.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (45,126,000)</p></td>\n <td><p>-196.6%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,767,000)</p></td>\n <td><p>-313.4%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Net Income (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Net Income (Loss)</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 32,840,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (47,352,000)</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,606,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Cash Flow From Operations</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Cash Flow From Operations</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ (37,812,000)</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 92,655,000</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (12,996,000)</p></td>\n </tr>\n </tbody>\n</table>\n<p>As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Measure [TTM]</b></p></td>\n <td><p><b>Amount</b></p></td>\n </tr>\n <tr>\n <td><p>Market Capitalization at IPO</p></td>\n <td><p>$2,299,981,232</p></td>\n </tr>\n <tr>\n <td><p>Enterprise Value</p></td>\n <td><p>$1,874,455,232</p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>10.46</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>8.52</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>35.46</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$0.03</p></td>\n </tr>\n <tr>\n <td><p>Float To Outstanding Shares Ratio</p></td>\n <td><p>8.70%</p></td>\n </tr>\n <tr>\n <td><p>Proposed IPO Midpoint Price per Share</p></td>\n <td><p>$16.00</p></td>\n </tr>\n <tr>\n <td><p>Net Free Cash Flow</p></td>\n <td><p>-$59,920,000</p></td>\n </tr>\n <tr>\n <td><p>Free Cash Flow Yield Per Share</p></td>\n <td><p>-2.61%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>3971.01%</p></td>\n </tr>\n </tbody>\n</table>\n<p>As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Metric</b></p></td>\n <td><p><b>Bio-Rad (BIO)</b></p></td>\n <td><p><b>Cue Health (HLTH)</b></p></td>\n <td><p><b>Variance</b></p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>8.15</p></td>\n <td><p>10.46</p></td>\n <td><p>28.3%</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>7.82</p></td>\n <td><p>8.52</p></td>\n <td><p>9.0%</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>31.66</p></td>\n <td><p>35.46</p></td>\n <td><p>12.0%</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$134.05</p></td>\n <td><p>$0.03</p></td>\n <td><p>-100.0%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>25.6%</p></td>\n <td><p>3971.01%</p></td>\n <td><p>15436.03%</p></td>\n </tr>\n <tr>\n <td><p>(Glossary Of Terms)</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Commentary</b></p>\n<p>Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p>\n<p>The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p>\n<p>The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p>\n<p>Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p>\n<p>As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p>\n<p>Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-24 23:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p>\n<p><img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Company & Technology</b></p>\n<p>San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p>\n<p>Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p>\n<p>The company’s primary offerings in its Cue Integrated Care Platform:</p>\n<ul>\n <li><p>Health monitoring system</p></li>\n <li><p>Rader</p></li>\n <li><p>Cartridge</p></li>\n <li><p>Wand</p></li>\n <li><p>Data</p></li>\n <li><p>Delivery apps</p></li>\n <li><p>Enterprise dashboard</p></li>\n <li><p>Ecosystem integrations</p></li>\n</ul>\n<p>Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p>\n<p><b>Customer/User Acquisition</b></p>\n<p>The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p>\n<p>Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Expenses vs. Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Percentage</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>1.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>3.1%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>1.3%</p></td>\n </tr>\n </tbody>\n</table>\n<p>The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Efficiency Rate</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Multiple</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>100.5</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>22.9</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Market & Competition</b></p>\n<p>According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p>\n<p>This represents a forecast CAGR of 5.05% from 2021 to 2027.</p>\n<p>The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p>\n<p>Also, below is a chart showing the market share of use of detection kits by end-user type:</p>\n<p><img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>(Source)</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li><p>Abbott Laboratories(NYSE:ABT)</p></li>\n <li><p>Becton, Dickinson(NYSE:BDX)</p></li>\n <li><p>bioMerieux(OTCPK:BMXMF)</p></li>\n <li><p>Bio-Rad Laboratories(NYSE:BIO)</p></li>\n <li><p>Danaher(NYSE:DHR)</p></li>\n <li><p>Ellume Limited</p></li>\n <li><p>Everly Health</p></li>\n <li><p>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p></li>\n <li><p>Fluidigm(NASDAQ:FLDM)</p></li>\n <li><p>GenMark Diagnostics(NASDAQ:GNMK)</p></li>\n <li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Cue’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Sharply growing top line revenue</p></li>\n <li><p>Increasing gross profit and variable gross margin</p></li>\n <li><p>A swing to operating profit and net income</p></li>\n <li><p>Variable cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Total Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Total Revenue</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 201,922,000</p></td>\n <td><p>3971.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 22,953,000</p></td>\n <td><p>246.4%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Profit (Loss)</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 116,745,000</p></td>\n <td><p>2253.7%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 8,002,000</p></td>\n <td><p>20.8%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Margin</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>57.82%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>34.86%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>100.00%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Operating Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Operating Profit (Loss)</p></td>\n <td><p>Operating Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 79,463,000</p></td>\n <td><p>39.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (45,126,000)</p></td>\n <td><p>-196.6%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,767,000)</p></td>\n <td><p>-313.4%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Net Income (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Net Income (Loss)</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 32,840,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (47,352,000)</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,606,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Cash Flow From Operations</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Cash Flow From Operations</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ (37,812,000)</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 92,655,000</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (12,996,000)</p></td>\n </tr>\n </tbody>\n</table>\n<p>As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Measure [TTM]</b></p></td>\n <td><p><b>Amount</b></p></td>\n </tr>\n <tr>\n <td><p>Market Capitalization at IPO</p></td>\n <td><p>$2,299,981,232</p></td>\n </tr>\n <tr>\n <td><p>Enterprise Value</p></td>\n <td><p>$1,874,455,232</p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>10.46</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>8.52</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>35.46</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$0.03</p></td>\n </tr>\n <tr>\n <td><p>Float To Outstanding Shares Ratio</p></td>\n <td><p>8.70%</p></td>\n </tr>\n <tr>\n <td><p>Proposed IPO Midpoint Price per Share</p></td>\n <td><p>$16.00</p></td>\n </tr>\n <tr>\n <td><p>Net Free Cash Flow</p></td>\n <td><p>-$59,920,000</p></td>\n </tr>\n <tr>\n <td><p>Free Cash Flow Yield Per Share</p></td>\n <td><p>-2.61%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>3971.01%</p></td>\n </tr>\n </tbody>\n</table>\n<p>As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Metric</b></p></td>\n <td><p><b>Bio-Rad (BIO)</b></p></td>\n <td><p><b>Cue Health (HLTH)</b></p></td>\n <td><p><b>Variance</b></p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>8.15</p></td>\n <td><p>10.46</p></td>\n <td><p>28.3%</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>7.82</p></td>\n <td><p>8.52</p></td>\n <td><p>9.0%</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>31.66</p></td>\n <td><p>35.46</p></td>\n <td><p>12.0%</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$134.05</p></td>\n <td><p>$0.03</p></td>\n <td><p>-100.0%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>25.6%</p></td>\n <td><p>3971.01%</p></td>\n <td><p>15436.03%</p></td>\n </tr>\n <tr>\n <td><p>(Glossary Of Terms)</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Commentary</b></p>\n<p>Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p>\n<p>The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p>\n<p>The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p>\n<p>Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p>\n<p>As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p>\n<p>Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLTH":"Cue Health Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104085778","content_text":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n\nHealth monitoring system\nRader\nCartridge\nWand\nData\nDelivery apps\nEnterprise dashboard\nEcosystem integrations\n\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n\n\n\nSales and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n1.0%\n\n\n2020\n3.1%\n\n\n2019\n1.3%\n\n\n\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n\n\n\nSales and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n100.5\n\n\n2020\n22.9\n\n\n\nMarket & Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n\n(Source)\nMajor competitive or other industry participants include:\n\nAbbott Laboratories(NYSE:ABT)\nBecton, Dickinson(NYSE:BDX)\nbioMerieux(OTCPK:BMXMF)\nBio-Rad Laboratories(NYSE:BIO)\nDanaher(NYSE:DHR)\nEllume Limited\nEverly Health\nRoche(OTCQX:RHHBY)(OTCQX:RHHBF)\nFluidigm(NASDAQ:FLDM)\nGenMark Diagnostics(NASDAQ:GNMK)\nOthers\n\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n\nSharply growing top line revenue\nIncreasing gross profit and variable gross margin\nA swing to operating profit and net income\nVariable cash flow from operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 201,922,000\n3971.0%\n\n\n2020\n$ 22,953,000\n246.4%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 116,745,000\n2253.7%\n\n\n2020\n$ 8,002,000\n20.8%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n57.82%\n\n\n2020\n34.86%\n\n\n2019\n100.00%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 79,463,000\n39.4%\n\n\n2020\n$ (45,126,000)\n-196.6%\n\n\n2019\n$ (20,767,000)\n-313.4%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 32,840,000\n\n\n2020\n$ (47,352,000)\n\n\n2019\n$ (20,606,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ (37,812,000)\n\n\n2020\n$ 92,655,000\n\n\n2019\n$ (12,996,000)\n\n\n\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$2,299,981,232\n\n\nEnterprise Value\n$1,874,455,232\n\n\nPrice / Sales\n10.46\n\n\nEV / Revenue\n8.52\n\n\nEV / EBITDA\n35.46\n\n\nEarnings Per Share\n$0.03\n\n\nFloat To Outstanding Shares Ratio\n8.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$59,920,000\n\n\nFree Cash Flow Yield Per Share\n-2.61%\n\n\nRevenue Growth Rate\n3971.01%\n\n\n\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nBio-Rad (BIO)\nCue Health (HLTH)\nVariance\n\n\nPrice / Sales\n8.15\n10.46\n28.3%\n\n\nEV / Revenue\n7.82\n8.52\n9.0%\n\n\nEV / EBITDA\n31.66\n35.46\n12.0%\n\n\nEarnings Per Share\n$134.05\n$0.03\n-100.0%\n\n\nRevenue Growth Rate\n25.6%\n3971.01%\n15436.03%\n\n\n(Glossary Of Terms)\n\n\n\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861776516,"gmtCreate":1632543442035,"gmtModify":1632799215041,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORCL\">$Oracle(ORCL)$</a>good recovery and stable","listText":"<a href=\"https://laohu8.com/S/ORCL\">$Oracle(ORCL)$</a>good recovery and stable","text":"$Oracle(ORCL)$good recovery and stable","images":[{"img":"https://static.tigerbbs.com/b547f97d6af2bdde2f9520ba3b5867ce","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861776516","isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":866822925,"gmtCreate":1632754809667,"gmtModify":1632798059258,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/866822925","repostId":"1123391790","repostType":4,"repost":{"id":"1123391790","pubTimestamp":1632754543,"share":"https://www.laohu8.com/m/news/1123391790?lang=&edition=full","pubTime":"2021-09-27 22:55","market":"us","language":"en","title":"ASML: It's Time To Take Profits","url":"https://stock-news.laohu8.com/highlight/detail?id=1123391790","media":"Seeking Alpha","summary":"Summary\n\nWe wrote a bullish article on ASML more than two years ago, since then it has significantly","content":"<p><b>Summary</b></p>\n<ul>\n <li>We wrote a bullish article on ASML more than two years ago, since then it has significantly outperformed both the S&P500 and our own expectations.</li>\n <li>ASML is firing on all cylinders, but the valuation has become extremely stretched and we believe it is time to take profits or at least reduce the position.</li>\n <li>We are positive on the company's fundamentals and still believe extreme ultraviolet technology is the future of chip manufacturing.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cbbfa8ed4239d6e8d29d42367fc89fa\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Michael Vi/iStock Editorial via Getty Images</span></p>\n<p>We wrote a bullish article on ASML(NASDAQ:ASML) more than two years ago, since then it has significantly outperformed both the S&P500 and our own expectations.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ebeefb02d1c446db8e52248f8743ecf3\" tg-width=\"257\" tg-height=\"202\" width=\"100%\" height=\"auto\"><span>Source: Seeking Alpha</span></p>\n<p>Part of our thesis was that the industry was becoming a natural monopoly since few could match the extreme investment and R&D needed, this is what we said back then:</p>\n<blockquote>\n Increasing complexity and R&D costs have raised the stakes to a point where few companies will be able to compete in the future, increasing returns for the few left standing.\n</blockquote>\n<p>We also mentioned that the time had come for years of significant R&D investment to pay off, and it seems we were right given the exponential growth in its gross profit as seen in the graph below.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7695b604564361609481c3be5ba51ee5\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>While shares deserve a high price/sales multiple given the record gross profit margins, we believe it has gotten too stretched at ~18x.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b58849fe01d66780fe4568ad581e3496\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>Part of the bullish thesis with ASML is that despite the cyclicality of its revenue, it's easy to observe that there is also a secular trend higher. ASML is increasing its market share and the industry is becoming almost a monopoly. ASML is turning out to be the only game in town when it comes to extreme ultraviolet (EUV) equipment, and customers are buying more equipment to meet the increases in semiconductor demand.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1846ea5e83cafd797cb6cc34fb9b9aa4\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>As revenue increases and the company becomes more successful it is not reducing R&D expense, but instead is doubling down with more money dedicated than ever to R&D. We like that the company keeps investing in its future, and this will make it increasingly difficult for competitors to ever catch up.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/640dbaeb6546cb17ae3d44efe00a9dbc\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><b>Valuation</b></p>\n<p>When we wrote the bullish article in 2019 shares were trading at an EV/EBITDA of ~18x, and now shares are almost 3x times more expensive based on this valuation multiple. Share price increases have clearly surpassed increases in profitability. We believe this is not sustainable and either business fundamentals catch up with the share price, or the share price adjusts to a more reasonable multiple.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b0e53eb278ed1ce84114574a338bf8b5\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>One thing that has not changed is the strength of the company's balance sheet. The company continues to have a net positive cash position and a very healthy quick ratio above 1.0 having more quick assets than current liabilities.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/49a616b21047d8945929adab5654c491\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>Back in 2019 the dividend was ~1%, and the company had just announced that it intended to increase it by 50%. Today, while the company continues rewarding shareholders with a dividend and share repurchases, the yield has become a minuscule 0.38%. The shareholder yield, which incorporates both the dividend and share repurchases, is a little better at 2% compared to ~3% back in 2019. These statistics and dividend compression reflect how expensive shares have gotten. We also think that share buybacks should be postponed until the share price is closer to the intrinsic value of the company.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/16e4d38a523ce2586faa9b0e572aaadb\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>Finally, the forward P/E ratio does an excellent job capturing how expensive shares have gotten. Back in 2019 shares were trading at a TTM and forward P/E of ~24x each. Both of these multiples have more than doubled since then.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fe1468398d132f9200083378aa535dd7\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><b>Competitive Advantages</b></p>\n<p>What we predicted about ASML's competitive advantages becoming stronger has come to pass. ASML is basically selling all the machines it can manufacture with its order book filling, and it is projecting a trillion dollar semiconductor market by 2030, twice its size today. Given the strength of their current offering and the fact that the company is still investing heavily in R&D to further improve the machines, it is likely that ASML will capture a lot of the CapEx needed to double the production capacity of the industry.</p>\n<p>Looking back, this was our reasoning back then which led us to predict the company would come to dominate its industry:</p>\n<p>While we believe the market is currently valuing ASML as a high-quality technology company with significant growth opportunities ahead, it appears the market is missing just how critical EUV lithography technology can become.</p>\n<p>The investments to keep Moore's Law alive and technology nodes shrinking are rising quickly as the complexity of the machines increases and the needed R&D investments go up. This raises the stakes with every new generation forcing competitors out, giving the few remaining companies more pricing power and making their intellectual property more valuable. Some analysts however are starting to grasp the significance of these developments. For example, InsingerGilissen Bankiers analyst Jos Versteeg told Bloomberg:</p>\n<p>ASML sees in its order portfolio it looks well for overall 2019, for a major part because it moves into EUV, in which they are the only player. The future for the coming seven years looks very bright.</p>\n<p>These are incredibly complex machines that weigh more than a 100 tons, require the use of high-powered lasers and plasma, and took years and incredible amounts of engineering ingenuity to get to work.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/973b1626dc094982f58ff77dc14b4098\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"><span>Source: ASML investor presentation</span></p>\n<p>Not only is EUV lithography technology critical to keep shrinking technology nodes, but its adoption also has some side benefits for customers. These include cycle time reductions, process simplification, and cost reductions.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a2abd6a60053e447cab0b1f2abb3ed64\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"><span>Source: ASML investor presentation</span></p>\n<p>For these reasons several semiconductor technology leaders are building significant capacity for EUV systems.</p>\n<p><b>Conclusion</b></p>\n<p>While ASML's fundamentals remain as strong as ever, we believe most of the good news is already reflected in the share price. We think right now is a good moment to sell, or at least pair down the investment. ASML is truly a one-of-a-kind company that dominates its industry in a way that rarely happens. It has left competitors in the dust and is growing with good profitability and attractive margins. However, at the end of the day a successful investment is as much the quality of the company as it is the price paid, and currently the price is very high.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASML: It's Time To Take Profits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASML: It's Time To Take Profits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-27 22:55 GMT+8 <a href=https://seekingalpha.com/article/4457186-asml-its-time-to-take-profits><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nWe wrote a bullish article on ASML more than two years ago, since then it has significantly outperformed both the S&P500 and our own expectations.\nASML is firing on all cylinders, but the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4457186-asml-its-time-to-take-profits\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ASML":"阿斯麦"},"source_url":"https://seekingalpha.com/article/4457186-asml-its-time-to-take-profits","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123391790","content_text":"Summary\n\nWe wrote a bullish article on ASML more than two years ago, since then it has significantly outperformed both the S&P500 and our own expectations.\nASML is firing on all cylinders, but the valuation has become extremely stretched and we believe it is time to take profits or at least reduce the position.\nWe are positive on the company's fundamentals and still believe extreme ultraviolet technology is the future of chip manufacturing.\n\nMichael Vi/iStock Editorial via Getty Images\nWe wrote a bullish article on ASML(NASDAQ:ASML) more than two years ago, since then it has significantly outperformed both the S&P500 and our own expectations.\nSource: Seeking Alpha\nPart of our thesis was that the industry was becoming a natural monopoly since few could match the extreme investment and R&D needed, this is what we said back then:\n\n Increasing complexity and R&D costs have raised the stakes to a point where few companies will be able to compete in the future, increasing returns for the few left standing.\n\nWe also mentioned that the time had come for years of significant R&D investment to pay off, and it seems we were right given the exponential growth in its gross profit as seen in the graph below.\nData by YCharts\nWhile shares deserve a high price/sales multiple given the record gross profit margins, we believe it has gotten too stretched at ~18x.\nData by YCharts\nPart of the bullish thesis with ASML is that despite the cyclicality of its revenue, it's easy to observe that there is also a secular trend higher. ASML is increasing its market share and the industry is becoming almost a monopoly. ASML is turning out to be the only game in town when it comes to extreme ultraviolet (EUV) equipment, and customers are buying more equipment to meet the increases in semiconductor demand.\nData by YCharts\nAs revenue increases and the company becomes more successful it is not reducing R&D expense, but instead is doubling down with more money dedicated than ever to R&D. We like that the company keeps investing in its future, and this will make it increasingly difficult for competitors to ever catch up.\nData by YCharts\nValuation\nWhen we wrote the bullish article in 2019 shares were trading at an EV/EBITDA of ~18x, and now shares are almost 3x times more expensive based on this valuation multiple. Share price increases have clearly surpassed increases in profitability. We believe this is not sustainable and either business fundamentals catch up with the share price, or the share price adjusts to a more reasonable multiple.\nData by YCharts\nOne thing that has not changed is the strength of the company's balance sheet. The company continues to have a net positive cash position and a very healthy quick ratio above 1.0 having more quick assets than current liabilities.\nData by YCharts\nBack in 2019 the dividend was ~1%, and the company had just announced that it intended to increase it by 50%. Today, while the company continues rewarding shareholders with a dividend and share repurchases, the yield has become a minuscule 0.38%. The shareholder yield, which incorporates both the dividend and share repurchases, is a little better at 2% compared to ~3% back in 2019. These statistics and dividend compression reflect how expensive shares have gotten. We also think that share buybacks should be postponed until the share price is closer to the intrinsic value of the company.\nData by YCharts\nFinally, the forward P/E ratio does an excellent job capturing how expensive shares have gotten. Back in 2019 shares were trading at a TTM and forward P/E of ~24x each. Both of these multiples have more than doubled since then.\nData by YCharts\nCompetitive Advantages\nWhat we predicted about ASML's competitive advantages becoming stronger has come to pass. ASML is basically selling all the machines it can manufacture with its order book filling, and it is projecting a trillion dollar semiconductor market by 2030, twice its size today. Given the strength of their current offering and the fact that the company is still investing heavily in R&D to further improve the machines, it is likely that ASML will capture a lot of the CapEx needed to double the production capacity of the industry.\nLooking back, this was our reasoning back then which led us to predict the company would come to dominate its industry:\nWhile we believe the market is currently valuing ASML as a high-quality technology company with significant growth opportunities ahead, it appears the market is missing just how critical EUV lithography technology can become.\nThe investments to keep Moore's Law alive and technology nodes shrinking are rising quickly as the complexity of the machines increases and the needed R&D investments go up. This raises the stakes with every new generation forcing competitors out, giving the few remaining companies more pricing power and making their intellectual property more valuable. Some analysts however are starting to grasp the significance of these developments. For example, InsingerGilissen Bankiers analyst Jos Versteeg told Bloomberg:\nASML sees in its order portfolio it looks well for overall 2019, for a major part because it moves into EUV, in which they are the only player. The future for the coming seven years looks very bright.\nThese are incredibly complex machines that weigh more than a 100 tons, require the use of high-powered lasers and plasma, and took years and incredible amounts of engineering ingenuity to get to work.\nSource: ASML investor presentation\nNot only is EUV lithography technology critical to keep shrinking technology nodes, but its adoption also has some side benefits for customers. These include cycle time reductions, process simplification, and cost reductions.\nSource: ASML investor presentation\nFor these reasons several semiconductor technology leaders are building significant capacity for EUV systems.\nConclusion\nWhile ASML's fundamentals remain as strong as ever, we believe most of the good news is already reflected in the share price. We think right now is a good moment to sell, or at least pair down the investment. ASML is truly a one-of-a-kind company that dominates its industry in a way that rarely happens. It has left competitors in the dust and is growing with good profitability and attractive margins. However, at the end of the day a successful investment is as much the quality of the company as it is the price paid, and currently the price is very high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856175880,"gmtCreate":1635165537110,"gmtModify":1635165537636,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>ddont panicd just hodl","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>ddont panicd just hodl","text":"$Tiger Brokers(TIGR)$ddont panicd just hodl","images":[{"img":"https://static.tigerbbs.com/372650c68945d62b9e598e769325bdee","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/856175880","isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879488314,"gmtCreate":1636763712834,"gmtModify":1636763712977,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/879488314","repostId":"1169510701","repostType":4,"repost":{"id":"1169510701","pubTimestamp":1636759821,"share":"https://www.laohu8.com/m/news/1169510701?lang=&edition=full","pubTime":"2021-11-13 07:30","market":"us","language":"en","title":"Buy the Elon Musk Dip in Tesla Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=1169510701","media":"TheStreet","summary":"Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk","content":"<p>Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk continues to sell.</p>\n<p>Tesla shares have been incredibly volatile this week. The stock fell 2.8% on Friday as investors try to sort out the next direction.</p>\n<p>Amid the recent slide — and perhaps one could say it triggered the decline — is CEO Elon Musk’s recent selling.</p>\n<p>Over the weekend, Musk ran a Twitter pollasking if he should sellsome of his shares.</p>\n<p>That led to a near-5% decline in Monday’s session, followed by a 12% haircut on Tuesday.</p>\n<p>He had sold more than $5 billion worth of stock earlier this week. Another $650 million was reported this morning.</p>\n<p>Referencing when I said “perhaps” Musk caused the recent selloff, many will say that is indeed the case and there’s no need to leave it to question.</p>\n<p>That may be true in some regards, but the stock shifted into a parabolic state this quarter.</p>\n<p>From Oct. 25 to the Nov. 4 high — covering just nine trading sessions — shares gained more than 30%.</p>\n<p>From Oct. 1 to those highs, the gain swells to almost 63%, while the run from the Aug. 17 low made less than three months sit at more than 91%.</p>\n<p>In other words, yes, the Musk headlines may have triggered the selling. But after such a meteoric run and after garnering a $1.2 trillion valuation near the high, Tesla stock was due for a correction regardless of which headline caused it.</p>\n<p><b>Trading Tesla Stock</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d6b8cde52218f9b3a6d0598de04b7a6b\" tg-width=\"1023\" tg-height=\"735\" width=\"100%\" height=\"auto\"><span>Daily chart of Tesla stock.</span></p>\n<p>Look at how wobbly this name has been, as the volatility and headline risks have ramped up over that past few days.</p>\n<p>We’ll likely see some “chest-pounding” by the Tesla bears, but don’t let them fool you — this stock has been explosive on the upside. The stock is up 150% over the past year and up over 1,300% over the past three years.</p>\n<p>As one of the few U.S. companies to hit a $1 trillion market cap, it’s perhaps the furthest thing from “TeslaQ” one could imagine.</p>\n<p>Despite the run, bulls are trying to buy the dip. Shares bounced hard at the 21-day moving average, but are threatening to lose that measure today.</p>\n<p>If it does, this week’s low near $987 is vulnerable. If Tesla breaks below it, the 10-week moving average could be in play. That’s followed by the $910 gap-fill and the 50-day moving average.</p>\n<p>On the upside, let’s see if Tesla can reclaim the 10-day moving average. A close over $1,100 repairs a lot of damage and opens up the $1,200 to $1,250 area.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy the Elon Musk Dip in Tesla Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy the Elon Musk Dip in Tesla Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 07:30 GMT+8 <a href=https://www.thestreet.com/investing/trading-tesla-tsla-stock-pullback-elon-musk-insider-selling><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk continues to sell.\nTesla shares have been incredibly volatile this week. The stock fell 2.8% on ...</p>\n\n<a href=\"https://www.thestreet.com/investing/trading-tesla-tsla-stock-pullback-elon-musk-insider-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/investing/trading-tesla-tsla-stock-pullback-elon-musk-insider-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169510701","content_text":"Tesla stock has been incredibly volatile over the past week. Here's how to trade it as CEO Elon Musk continues to sell.\nTesla shares have been incredibly volatile this week. The stock fell 2.8% on Friday as investors try to sort out the next direction.\nAmid the recent slide — and perhaps one could say it triggered the decline — is CEO Elon Musk’s recent selling.\nOver the weekend, Musk ran a Twitter pollasking if he should sellsome of his shares.\nThat led to a near-5% decline in Monday’s session, followed by a 12% haircut on Tuesday.\nHe had sold more than $5 billion worth of stock earlier this week. Another $650 million was reported this morning.\nReferencing when I said “perhaps” Musk caused the recent selloff, many will say that is indeed the case and there’s no need to leave it to question.\nThat may be true in some regards, but the stock shifted into a parabolic state this quarter.\nFrom Oct. 25 to the Nov. 4 high — covering just nine trading sessions — shares gained more than 30%.\nFrom Oct. 1 to those highs, the gain swells to almost 63%, while the run from the Aug. 17 low made less than three months sit at more than 91%.\nIn other words, yes, the Musk headlines may have triggered the selling. But after such a meteoric run and after garnering a $1.2 trillion valuation near the high, Tesla stock was due for a correction regardless of which headline caused it.\nTrading Tesla Stock\nDaily chart of Tesla stock.\nLook at how wobbly this name has been, as the volatility and headline risks have ramped up over that past few days.\nWe’ll likely see some “chest-pounding” by the Tesla bears, but don’t let them fool you — this stock has been explosive on the upside. The stock is up 150% over the past year and up over 1,300% over the past three years.\nAs one of the few U.S. companies to hit a $1 trillion market cap, it’s perhaps the furthest thing from “TeslaQ” one could imagine.\nDespite the run, bulls are trying to buy the dip. Shares bounced hard at the 21-day moving average, but are threatening to lose that measure today.\nIf it does, this week’s low near $987 is vulnerable. If Tesla breaks below it, the 10-week moving average could be in play. That’s followed by the $910 gap-fill and the 50-day moving average.\nOn the upside, let’s see if Tesla can reclaim the 10-day moving average. A close over $1,100 repairs a lot of damage and opens up the $1,200 to $1,250 area.","news_type":1},"isVote":1,"tweetType":1,"viewCount":400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852689991,"gmtCreate":1635261755078,"gmtModify":1635261756390,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Get ready to put in","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>Get ready to put in","text":"$GLOBALFOUNDRIES Inc.(GFS)$Get ready to put in","images":[{"img":"https://static.tigerbbs.com/c355c8ff71101a2a48133293fdead1e8","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/852689991","isVote":1,"tweetType":1,"viewCount":1201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861772701,"gmtCreate":1632543549303,"gmtModify":1632799214056,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good way","listText":"Good way","text":"Good way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861772701","repostId":"1104085778","repostType":4,"repost":{"id":"1104085778","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632498166,"share":"https://www.laohu8.com/m/news/1104085778?lang=&edition=full","pubTime":"2021-09-24 23:42","market":"us","language":"en","title":"IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.","url":"https://stock-news.laohu8.com/highlight/detail?id=1104085778","media":"Tiger Newspress","summary":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nS","content":"<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p>\n<p><img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Company & Technology</b></p>\n<p>San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p>\n<p>Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p>\n<p>The company’s primary offerings in its Cue Integrated Care Platform:</p>\n<ul>\n <li><p>Health monitoring system</p></li>\n <li><p>Rader</p></li>\n <li><p>Cartridge</p></li>\n <li><p>Wand</p></li>\n <li><p>Data</p></li>\n <li><p>Delivery apps</p></li>\n <li><p>Enterprise dashboard</p></li>\n <li><p>Ecosystem integrations</p></li>\n</ul>\n<p>Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p>\n<p><b>Customer/User Acquisition</b></p>\n<p>The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p>\n<p>Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Expenses vs. Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Percentage</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>1.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>3.1%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>1.3%</p></td>\n </tr>\n </tbody>\n</table>\n<p>The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Efficiency Rate</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Multiple</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>100.5</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>22.9</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Market & Competition</b></p>\n<p>According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p>\n<p>This represents a forecast CAGR of 5.05% from 2021 to 2027.</p>\n<p>The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p>\n<p>Also, below is a chart showing the market share of use of detection kits by end-user type:</p>\n<p><img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>(Source)</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li><p>Abbott Laboratories(NYSE:ABT)</p></li>\n <li><p>Becton, Dickinson(NYSE:BDX)</p></li>\n <li><p>bioMerieux(OTCPK:BMXMF)</p></li>\n <li><p>Bio-Rad Laboratories(NYSE:BIO)</p></li>\n <li><p>Danaher(NYSE:DHR)</p></li>\n <li><p>Ellume Limited</p></li>\n <li><p>Everly Health</p></li>\n <li><p>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p></li>\n <li><p>Fluidigm(NASDAQ:FLDM)</p></li>\n <li><p>GenMark Diagnostics(NASDAQ:GNMK)</p></li>\n <li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Cue’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Sharply growing top line revenue</p></li>\n <li><p>Increasing gross profit and variable gross margin</p></li>\n <li><p>A swing to operating profit and net income</p></li>\n <li><p>Variable cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Total Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Total Revenue</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 201,922,000</p></td>\n <td><p>3971.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 22,953,000</p></td>\n <td><p>246.4%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Profit (Loss)</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 116,745,000</p></td>\n <td><p>2253.7%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 8,002,000</p></td>\n <td><p>20.8%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Margin</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>57.82%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>34.86%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>100.00%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Operating Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Operating Profit (Loss)</p></td>\n <td><p>Operating Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 79,463,000</p></td>\n <td><p>39.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (45,126,000)</p></td>\n <td><p>-196.6%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,767,000)</p></td>\n <td><p>-313.4%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Net Income (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Net Income (Loss)</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 32,840,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (47,352,000)</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,606,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Cash Flow From Operations</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Cash Flow From Operations</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ (37,812,000)</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 92,655,000</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (12,996,000)</p></td>\n </tr>\n </tbody>\n</table>\n<p>As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Measure [TTM]</b></p></td>\n <td><p><b>Amount</b></p></td>\n </tr>\n <tr>\n <td><p>Market Capitalization at IPO</p></td>\n <td><p>$2,299,981,232</p></td>\n </tr>\n <tr>\n <td><p>Enterprise Value</p></td>\n <td><p>$1,874,455,232</p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>10.46</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>8.52</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>35.46</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$0.03</p></td>\n </tr>\n <tr>\n <td><p>Float To Outstanding Shares Ratio</p></td>\n <td><p>8.70%</p></td>\n </tr>\n <tr>\n <td><p>Proposed IPO Midpoint Price per Share</p></td>\n <td><p>$16.00</p></td>\n </tr>\n <tr>\n <td><p>Net Free Cash Flow</p></td>\n <td><p>-$59,920,000</p></td>\n </tr>\n <tr>\n <td><p>Free Cash Flow Yield Per Share</p></td>\n <td><p>-2.61%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>3971.01%</p></td>\n </tr>\n </tbody>\n</table>\n<p>As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Metric</b></p></td>\n <td><p><b>Bio-Rad (BIO)</b></p></td>\n <td><p><b>Cue Health (HLTH)</b></p></td>\n <td><p><b>Variance</b></p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>8.15</p></td>\n <td><p>10.46</p></td>\n <td><p>28.3%</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>7.82</p></td>\n <td><p>8.52</p></td>\n <td><p>9.0%</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>31.66</p></td>\n <td><p>35.46</p></td>\n <td><p>12.0%</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$134.05</p></td>\n <td><p>$0.03</p></td>\n <td><p>-100.0%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>25.6%</p></td>\n <td><p>3971.01%</p></td>\n <td><p>15436.03%</p></td>\n </tr>\n <tr>\n <td><p>(Glossary Of Terms)</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Commentary</b></p>\n<p>Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p>\n<p>The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p>\n<p>The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p>\n<p>Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p>\n<p>As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p>\n<p>Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-24 23:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p>\n<p><img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Company & Technology</b></p>\n<p>San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p>\n<p>Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p>\n<p>The company’s primary offerings in its Cue Integrated Care Platform:</p>\n<ul>\n <li><p>Health monitoring system</p></li>\n <li><p>Rader</p></li>\n <li><p>Cartridge</p></li>\n <li><p>Wand</p></li>\n <li><p>Data</p></li>\n <li><p>Delivery apps</p></li>\n <li><p>Enterprise dashboard</p></li>\n <li><p>Ecosystem integrations</p></li>\n</ul>\n<p>Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p>\n<p><b>Customer/User Acquisition</b></p>\n<p>The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p>\n<p>Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Expenses vs. Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Percentage</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>1.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>3.1%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>1.3%</p></td>\n </tr>\n </tbody>\n</table>\n<p>The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n <tr>\n <td><p><b>Sales and Marketing</b></p></td>\n <td><p><b>Efficiency Rate</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Multiple</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>100.5</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>22.9</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Market & Competition</b></p>\n<p>According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p>\n<p>This represents a forecast CAGR of 5.05% from 2021 to 2027.</p>\n<p>The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p>\n<p>Also, below is a chart showing the market share of use of detection kits by end-user type:</p>\n<p><img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>(Source)</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li><p>Abbott Laboratories(NYSE:ABT)</p></li>\n <li><p>Becton, Dickinson(NYSE:BDX)</p></li>\n <li><p>bioMerieux(OTCPK:BMXMF)</p></li>\n <li><p>Bio-Rad Laboratories(NYSE:BIO)</p></li>\n <li><p>Danaher(NYSE:DHR)</p></li>\n <li><p>Ellume Limited</p></li>\n <li><p>Everly Health</p></li>\n <li><p>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p></li>\n <li><p>Fluidigm(NASDAQ:FLDM)</p></li>\n <li><p>GenMark Diagnostics(NASDAQ:GNMK)</p></li>\n <li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Cue’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Sharply growing top line revenue</p></li>\n <li><p>Increasing gross profit and variable gross margin</p></li>\n <li><p>A swing to operating profit and net income</p></li>\n <li><p>Variable cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Total Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Total Revenue</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 201,922,000</p></td>\n <td><p>3971.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 22,953,000</p></td>\n <td><p>246.4%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Profit (Loss)</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 116,745,000</p></td>\n <td><p>2253.7%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 8,002,000</p></td>\n <td><p>20.8%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 6,626,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Margin</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>57.82%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>34.86%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>100.00%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Operating Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Operating Profit (Loss)</p></td>\n <td><p>Operating Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 79,463,000</p></td>\n <td><p>39.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (45,126,000)</p></td>\n <td><p>-196.6%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,767,000)</p></td>\n <td><p>-313.4%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Net Income (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Net Income (Loss)</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 32,840,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (47,352,000)</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (20,606,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Cash Flow From Operations</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Cash Flow From Operations</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ (37,812,000)</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 92,655,000</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (12,996,000)</p></td>\n </tr>\n </tbody>\n</table>\n<p>As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Measure [TTM]</b></p></td>\n <td><p><b>Amount</b></p></td>\n </tr>\n <tr>\n <td><p>Market Capitalization at IPO</p></td>\n <td><p>$2,299,981,232</p></td>\n </tr>\n <tr>\n <td><p>Enterprise Value</p></td>\n <td><p>$1,874,455,232</p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>10.46</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>8.52</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>35.46</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$0.03</p></td>\n </tr>\n <tr>\n <td><p>Float To Outstanding Shares Ratio</p></td>\n <td><p>8.70%</p></td>\n </tr>\n <tr>\n <td><p>Proposed IPO Midpoint Price per Share</p></td>\n <td><p>$16.00</p></td>\n </tr>\n <tr>\n <td><p>Net Free Cash Flow</p></td>\n <td><p>-$59,920,000</p></td>\n </tr>\n <tr>\n <td><p>Free Cash Flow Yield Per Share</p></td>\n <td><p>-2.61%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>3971.01%</p></td>\n </tr>\n </tbody>\n</table>\n<p>As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Metric</b></p></td>\n <td><p><b>Bio-Rad (BIO)</b></p></td>\n <td><p><b>Cue Health (HLTH)</b></p></td>\n <td><p><b>Variance</b></p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>8.15</p></td>\n <td><p>10.46</p></td>\n <td><p>28.3%</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>7.82</p></td>\n <td><p>8.52</p></td>\n <td><p>9.0%</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>31.66</p></td>\n <td><p>35.46</p></td>\n <td><p>12.0%</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$134.05</p></td>\n <td><p>$0.03</p></td>\n <td><p>-100.0%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>25.6%</p></td>\n <td><p>3971.01%</p></td>\n <td><p>15436.03%</p></td>\n </tr>\n <tr>\n <td><p>(Glossary Of Terms)</p></td>\n </tr>\n </tbody>\n</table>\n<p><b>Commentary</b></p>\n<p>Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p>\n<p>The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p>\n<p>The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p>\n<p>Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p>\n<p>As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p>\n<p>Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLTH":"Cue Health Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104085778","content_text":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n\nHealth monitoring system\nRader\nCartridge\nWand\nData\nDelivery apps\nEnterprise dashboard\nEcosystem integrations\n\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n\n\n\nSales and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n1.0%\n\n\n2020\n3.1%\n\n\n2019\n1.3%\n\n\n\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n\n\n\nSales and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n100.5\n\n\n2020\n22.9\n\n\n\nMarket & Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n\n(Source)\nMajor competitive or other industry participants include:\n\nAbbott Laboratories(NYSE:ABT)\nBecton, Dickinson(NYSE:BDX)\nbioMerieux(OTCPK:BMXMF)\nBio-Rad Laboratories(NYSE:BIO)\nDanaher(NYSE:DHR)\nEllume Limited\nEverly Health\nRoche(OTCQX:RHHBY)(OTCQX:RHHBF)\nFluidigm(NASDAQ:FLDM)\nGenMark Diagnostics(NASDAQ:GNMK)\nOthers\n\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n\nSharply growing top line revenue\nIncreasing gross profit and variable gross margin\nA swing to operating profit and net income\nVariable cash flow from operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 201,922,000\n3971.0%\n\n\n2020\n$ 22,953,000\n246.4%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 116,745,000\n2253.7%\n\n\n2020\n$ 8,002,000\n20.8%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n57.82%\n\n\n2020\n34.86%\n\n\n2019\n100.00%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 79,463,000\n39.4%\n\n\n2020\n$ (45,126,000)\n-196.6%\n\n\n2019\n$ (20,767,000)\n-313.4%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 32,840,000\n\n\n2020\n$ (47,352,000)\n\n\n2019\n$ (20,606,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ (37,812,000)\n\n\n2020\n$ 92,655,000\n\n\n2019\n$ (12,996,000)\n\n\n\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$2,299,981,232\n\n\nEnterprise Value\n$1,874,455,232\n\n\nPrice / Sales\n10.46\n\n\nEV / Revenue\n8.52\n\n\nEV / EBITDA\n35.46\n\n\nEarnings Per Share\n$0.03\n\n\nFloat To Outstanding Shares Ratio\n8.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$59,920,000\n\n\nFree Cash Flow Yield Per Share\n-2.61%\n\n\nRevenue Growth Rate\n3971.01%\n\n\n\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nBio-Rad (BIO)\nCue Health (HLTH)\nVariance\n\n\nPrice / Sales\n8.15\n10.46\n28.3%\n\n\nEV / Revenue\n7.82\n8.52\n9.0%\n\n\nEV / EBITDA\n31.66\n35.46\n12.0%\n\n\nEarnings Per Share\n$134.05\n$0.03\n-100.0%\n\n\nRevenue Growth Rate\n25.6%\n3971.01%\n15436.03%\n\n\n(Glossary Of Terms)\n\n\n\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870418129,"gmtCreate":1636641859614,"gmtModify":1636641860260,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OTLY\">$Oatly Group AB(OTLY)$</a>hhow is this not gaining traction?","listText":"<a href=\"https://laohu8.com/S/OTLY\">$Oatly Group AB(OTLY)$</a>hhow is this not gaining traction?","text":"$Oatly Group AB(OTLY)$hhow is this not gaining traction?","images":[{"img":"https://static.tigerbbs.com/c410eddcdf9824e4e15ae27e1e2d7f90","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870418129","isVote":1,"tweetType":1,"viewCount":513,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":840091261,"gmtCreate":1635565856126,"gmtModify":1635565856272,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>could this go all the way?","listText":"<a href=\"https://laohu8.com/S/GFS\">$GLOBALFOUNDRIES Inc.(GFS)$</a>could this go all the way?","text":"$GLOBALFOUNDRIES Inc.(GFS)$could this go all the way?","images":[{"img":"https://static.tigerbbs.com/28b4ce6183c4644156f6ef4046ea9fe1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840091261","isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":852461804,"gmtCreate":1635297486373,"gmtModify":1635297486847,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PROG\">$Progenity, Inc.(PROG)$</a>short or all in","listText":"<a href=\"https://laohu8.com/S/PROG\">$Progenity, Inc.(PROG)$</a>short or all in","text":"$Progenity, Inc.(PROG)$short or all in","images":[{"img":"https://static.tigerbbs.com/8d60f88529049f20b5c9375c60e61edc","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852461804","isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":856175788,"gmtCreate":1635165585294,"gmtModify":1635165585837,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DWAC\">$Digital World Acquisition Corp(DWAC)$</a>crazy movements ","listText":"<a href=\"https://laohu8.com/S/DWAC\">$Digital World Acquisition Corp(DWAC)$</a>crazy movements ","text":"$Digital World Acquisition Corp(DWAC)$crazy movements","images":[{"img":"https://static.tigerbbs.com/b185d1b16b8be8663c54dbcecef99e0d","width":"1080","height":"3148"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856175788","isVote":1,"tweetType":1,"viewCount":440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862499943,"gmtCreate":1632898759501,"gmtModify":1632898759995,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MVST\">$Microvast Holdings, Inc.(MVST)$</a>bbuy on the dip","listText":"<a href=\"https://laohu8.com/S/MVST\">$Microvast Holdings, Inc.(MVST)$</a>bbuy on the dip","text":"$Microvast Holdings, Inc.(MVST)$bbuy on the dip","images":[{"img":"https://static.tigerbbs.com/8d84016dd94afcebe8c68554bf1062f8","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862499943","isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861776516,"gmtCreate":1632543442035,"gmtModify":1632799215041,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORCL\">$Oracle(ORCL)$</a>good recovery and stable","listText":"<a href=\"https://laohu8.com/S/ORCL\">$Oracle(ORCL)$</a>good recovery and stable","text":"$Oracle(ORCL)$good recovery and stable","images":[{"img":"https://static.tigerbbs.com/b547f97d6af2bdde2f9520ba3b5867ce","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861776516","isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":852683302,"gmtCreate":1635261792725,"gmtModify":1635261793220,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ROKU\">$Roku Inc(ROKU)$</a>Where's the potential","listText":"<a href=\"https://laohu8.com/S/ROKU\">$Roku Inc(ROKU)$</a>Where's the potential","text":"$Roku Inc(ROKU)$Where's the potential","images":[{"img":"https://static.tigerbbs.com/182e6ac4d835bb7e0af2eb9db23541d6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852683302","isVote":1,"tweetType":1,"viewCount":374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":851569799,"gmtCreate":1634914953097,"gmtModify":1634914953570,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DVN\">$Devon(DVN)$</a>hhOly oil cow making waves","listText":"<a href=\"https://laohu8.com/S/DVN\">$Devon(DVN)$</a>hhOly oil cow making waves","text":"$Devon(DVN)$hhOly oil cow making waves","images":[{"img":"https://static.tigerbbs.com/127796045d4ddf75c028b2b1aa8e421a","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851569799","isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":829909950,"gmtCreate":1633446951159,"gmtModify":1633446982166,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>bounce bounce","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>bounce bounce","text":"$Clover Health Corp(CLOV)$bounce bounce","images":[{"img":"https://static.tigerbbs.com/180070dd8cf8f947865f83d5b017d79f","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829909950","isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862304553,"gmtCreate":1632836101835,"gmtModify":1632836102014,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>sso much for buying on the dip when it dipped further ","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>sso much for buying on the dip when it dipped further ","text":"$Pinterest, Inc.(PINS)$sso much for buying on the dip when it dipped further","images":[{"img":"https://static.tigerbbs.com/8848d21d72e018cd693111dc81c9a1fe","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862304553","isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":866826665,"gmtCreate":1632754772057,"gmtModify":1632798059753,"author":{"id":"3579391473717940","authorId":"3579391473717940","name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATVI\">$Activision Blizzard(ATVI)$</a>RReallt bruh","listText":"<a href=\"https://laohu8.com/S/ATVI\">$Activision Blizzard(ATVI)$</a>RReallt bruh","text":"$Activision Blizzard(ATVI)$RReallt bruh","images":[{"img":"https://static.tigerbbs.com/c1bc6fded0834787b6834b830b1e5855","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866826665","isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}